These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25471129)

  • 21. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
    Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
    Wanchoo R; Khan S; Kolitz JE; Jhaveri KD
    J Oncol Pharm Pract; 2015 Aug; 21(4):313-6. PubMed ID: 24748581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of acute liver failure due to carfilzomib in multiple myeloma.
    Kathi PR; Tama M; Kundumadam S; Naylor P; Mutchnick M
    J Clin Pharm Ther; 2018 Dec; 43(6):918-920. PubMed ID: 29969517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.
    Kawasaki A; Murakami H; Chou T; Matsushita M; Kizaki M
    Future Oncol; 2022 Aug; 18(24):2661-2674. PubMed ID: 35815645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma.
    Ghasoub R; Benkhadra M; Kassem N; Alshurafa A; Elsabah H
    J Oncol Pharm Pract; 2023 Dec; 29(8):2041-2044. PubMed ID: 37489075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).
    Lataifeh AR; Nusair A
    J Oncol Pharm Pract; 2016 Oct; 22(5):720-4. PubMed ID: 26044587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
    Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
    Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
    Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
    Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
    Zhao F; Yang B; Wang J; Zhang R; Liu J; Yin F; Xu W; He C
    Drug Des Devel Ther; 2018; 12():1525-1531. PubMed ID: 29881259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Veneto Region's Registry of Dialysis and Transplantation: 2006-2007 report].
    Antonucci F; Camerin E; Feriani M; Nordio M; Piccoli A; Rossi B; Tessitore N
    G Ital Nefrol; 2009; 26 Suppl 48():S5-56. PubMed ID: 19927265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.